SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas earnings beat has been overshadowed by concerns about sharply higher AI capital spending, negative free cash flow, and potential share issuance to help fund the buildout. Traders are split between viewing the post-earnings selloff as a buying opportunity near technical support and worrying that dilution and uncertain returns on AI investments could pressure the stock further.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Elon Musks warning that tighter debt markets could drive failures and consolidation among neocloud providers is weighing on Nebius and other AI-infrastructure stocks. Traders are split over whether Nebiuss financing and customer commitments set it apart or whether sector-wide funding and execution risks still threaten its expansion.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Lulas election victory triggered a broad selloff in Brazilian stocks, with traders linking NUs drop to uncertainty over Brazils fiscal direction and market outlook. The community is split between calling the decline an overreaction and buying opportunity, and expecting further downside.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is caught in a broad AI data-center selloff as traders react to Elon Musks warning that tighter financing could drive failures and consolidation among compute providers; they also cite the companys convertible-note offering as a source of dilution and selling pressure. Debate centers on whether CIFRs long-term leases and powered-site landlord model distinguish it from GPU-owning neoclouds, or whether sector financing and execution risks still weigh on the stock.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Lula da Silvas unexpected election victory over Flvio Bolsonaro has driven a sharp selloff in EWZ, as traders reassess Brazils political and fiscal outlook after markets had favored Bolsonaro. The community is split between seeing further downside from uncertainty and treating the drop as an overreaction or buying opportunity, with some noting the ETFs oil and commodity exposure may cushion losses.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

Elon Musks warning that many neocloud companies could fail or consolidate, alongside concerns about debt and tighter financing, is driving attention to IREN and its peers. Traders debate whether the comments highlight real risks to capital-intensive data-center expansion or are competitive FUD; bulls cite IRENs contracts and infrastructure, while bears worry about further losses.

XP, Inc. engages in the operation of technology-driven financial services platform. The firm provides customers with two principal types of offerings, financial advisory services for retail clients in Brazil, high-net-worth clients, international clients and corporate and institutional clients, and an open financial product platform providing access to over 800 investment products including equity and fixed income securities, mutual and hedge funds, structured products, life insurance, pension plans, real-estate investment funds (REITs) and others from XP, its partners and competitors. he company was founded by Guilherme Dias Fernandes Benchimol in 2001 and is headquartered in Vila Olimpia, Brazil.

XP Inc - Ordinary Shares - Class A

Brazilian election results and uncertainty over the countrys policy direction are driving attention to XP alongside other Brazilian stocks. Traders have debated whether the political shock warrants further selling or a rebound, with some seeing a more business-friendly balance of power as supportive for Brazilian equities.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Lulas election victory over Bolsonaro has put Petrobras and other Brazilian shares under pressure amid trader concerns about fiscal policy and political uncertainty. The community is split between viewing the selloff as a buying opportunity, citing Petrobrass oil assets and cash flow, and worrying about government influence and shareholder payouts.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibres quarterly results are driving attention: strong commerce and fintech growth was met with a post-earnings selloff as investors focused on falling profitability and margin pressure from logistics and credit investments. Bulls see the spending as a growth investment and are buying the dip, while bears question how soon margins can recover.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp semiconductor selloff, with traders focused on concerns that AI spending and debt may be unsustainable, alongside broader tech weakness. The community is split between expecting an oversold bounce or short squeeze and warning of further declines; many note that the funds 3x leverage magnifies volatility and losses.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOPR NewswireNEW YORK, Sept. 24, 2026 NEW YORK, Sept. 24, 2026 /PRNewswire...

Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy

Equity

Wall Street raised Ultragenyx’s price target after the U.S. Food and Drug Administration approved Fayuvi to treat children with Sanfilippo syndrome Type A.


ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells

Abeona stands to collect mid-single-digit royalties on sales of Ultragenyx’s Fayuvi plus up to $30 million in commercial milestone payments as part of a licensing deal.


INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOPR NewswireNEW YORK, Sept. 17, 2026 NEW YORK, Sept. 17, 2026 /PRNewswire...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO PR Newswire NEW YORK, Sept. 10, 2026 NEW YORK, Sept. 10, 2026...

ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abeona Therapeutics Inc. (Abeona or the Company) (NASDAQ: ABEO) for violations of the securities laws.INVESTIGATION DETAILS: The investigation...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026 /PRNewswire...

Abeona Therapeutics Q2 2026 Earnings Call Transcript

Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call.
This content is powered by Benzinga APIs. For comprehensive financial dataread more...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO) PR Newswire NEW YORK, July 27, 2026 NEW YORK, July 27...

Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Abeona Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Cantor Fitzgerald raised its price target on Ultragenyx to $39 from $33, maintaining an ‘Overweight’ rating, according to The Fly.</li><li>Citi increased RARE’s target to $32 from $31, pointing to a potentially meaningful commercial opportunity.</li><li>The Fayuvi approval also earned Ultragenyx a Priority Review Voucher, enabling quicker FDA review for a future drug application.</li></ul>Ultragenyx Pharmaceutical (RARE) was in the spotlight on Friday after a slew of price-target hikes following the U.S. Food and Drug Administration (FDA) approval of Fayuvi to treat children with Sanfilippo syndrome Type A.The approval comes just weeks after the company suffered a major setback in its Angelman syndrome program.At the time of writing, <a href="https://stocktwits.com/symbol/RARE">RARE</a> stock was up 1%, adding to its 12.6% rally in the previous session.<h2 class="st-heading-2">Priority Review Voucher: An Added Bonus</h2>Cantor Fitzgerald raised its price target on Ultragenyx to $39 from $33, maintaining an ‘Overweight’ rating, and called the <a href="https://stocktwits.com/news-articles/markets/equity/rare-stock-jumps-13-extends-gains-after-hours-as-fda-clears-first-sanfilippo-gene-therapy/cZtscCrRBdq">approval</a> a “much-needed win,” according to TheFly. This implies a 166% upside potential from current levels.The Fayuvi approval also earned Ultragenyx a Priority Review Voucher (PRV). A PRV enables a quicker FDA review for a future drug application or allows the biotech firm to sell the voucher to another company for cash.Cantor estimates that this voucher, together with another PRV previously received by the company, could potentially generate a combined $400 million in non-dilutive capital if monetized.Citi increased RARE’s target to $32 from $31 and kept a ‘Buy’ rating, calling Fayuvi’s label “favorable” and highlighting a potentially meaningful commercial opportunity. Canaccord also raised the target to $39 from $37 and maintained a ‘Buy’ rating.<h2 class="st-heading-2">ABEO Gets A Price Target Hike</h2>Separately, Cantor also raised Abeona Therapeutics (ABEO) price target to $30 from $28, keeping an ‘Overweight’ rating. The firm said Fayuvi approval could benefit Abeona through royalties of up to 10% on sales and up to $30 million in commercial milestone payments.ABEO shares climbed 3% in pre-market.<h2 class="st-heading-2">First Treatment For A Devastating Disease</h2>Fayuvi, also known as UX111, is a one-time gene therapy for certain pediatric patients with Sanfilippo syndrome Type A, an ultra-rare and fatal genetic disease that causes progressive damage to the brain.Fayuvi is Ultragenyx’s second approved gene therapy and sixth FDA-approved treatment overall. The company expects commercial supplies to begin shipping to qualified U.S. treatment centers within 30 to 60 days.The FDA had rejected the application last year over manufacturing issues.Earlier this month, Ultragenyx’s Phase 3 Aspire study of GTX-102 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-phase-3-aspire-results-angelman-syndrome">failed</a> to meet its primary goal in Angelman syndrome, another rare neurogenetic disorder, prompting the company to discontinue the program. The stock crashed more than 44% after the news.<h2 class="st-heading-2">Retail Bull Eyes $50</h2>Retail sentiment for RARE on Stocktwits turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours, amid ‘extremely high’ message volumes. RARE was also among the top trending tickers at the time of writing.One user expects the stock to hit $50.<stembedurl>https://stocktwits.com/AlbertAFT/message/664548043</stembedurl>RARE has been under heavy selling pressure so far in 2026, declining 38%.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/li-auto-reportedly-takes-the-xpeng-route-opens-self-developed-chips-ev-technology-to-external-customers/cZtutAtRB3Z">&nbsp;Li Auto Reportedly Takes The Xpeng Route – Opens Self-Developed Chips, EV Technology To External Customers</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ultragenyx Pharmaceutical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Wall Street raised Ultragenyx’s price target after the U.S. Food and Drug Administration approved Fayuvi to treat children with Sanfilippo syndrome Type A.

Ultragenyx Pharmaceutical Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.40
Prev Close	$4.47
Open	$4.42
Dividend Yield	0.00%
50-Day Moving Average	$5.40
Beta	0.80
Avg. Volume	1.41M
PE Ratio	-3.92

52-Week High	$7.65
52-Week Low	$4.00
Market Capitalization	$251.61M
EPS (Annual)	$1.01
Price to Book	1.97
Revenue Per Employee	$25,752.21

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABEO Fundamentals